Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Acquired by Northern Trust Corp

Northern Trust Corp increased its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 30.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 616,891 shares of the company's stock after purchasing an additional 145,205 shares during the quarter. Northern Trust Corp owned approximately 1.34% of Pacira BioSciences worth $11,622,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Sterling Capital Management LLC boosted its holdings in shares of Pacira BioSciences by 779.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,363 shares of the company's stock valued at $26,000 after buying an additional 1,208 shares in the last quarter. Caitlin John LLC lifted its position in Pacira BioSciences by 1,850.0% in the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company's stock valued at $35,000 after acquiring an additional 1,776 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in Pacira BioSciences by 495.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock valued at $62,000 after acquiring an additional 2,749 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Pacira BioSciences by 16.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock worth $68,000 after purchasing an additional 513 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Pacira BioSciences by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company's stock worth $184,000 after purchasing an additional 918 shares in the last quarter. 99.73% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PCRX has been the subject of a number of research analyst reports. Needham & Company LLC decreased their target price on Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating for the company in a research report on Friday, May 9th. HC Wainwright increased their price objective on Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a report on Tuesday, April 8th. Truist Financial upgraded shares of Pacira BioSciences from a "sell" rating to a "hold" rating and raised their target price for the stock from $8.00 to $25.00 in a research report on Thursday, January 30th. Finally, Barclays upped their price target on shares of Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a research report on Friday, February 28th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $26.44.

Pacira BioSciences Stock Performance

Pacira BioSciences stock traded down $0.50 during trading hours on Wednesday, reaching $26.25. 398,466 shares of the stock were exchanged, compared to its average volume of 970,094. Pacira BioSciences, Inc. has a 52-week low of $11.16 and a 52-week high of $31.64. The stock has a market cap of $1.22 billion, a P/E ratio of -12.92 and a beta of 0.56. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The firm's 50 day moving average is $25.04 and its 200 day moving average is $22.54.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.